This trial will enroll 300 people and the Pharma company, ROCHE, is investing $600 Million into this trial. Trial is for those who have been diagnosed with PD within the last two years but are not yet taking dopaminergic medication. They can be on a monoamine oxidase-B inhibitor such as rasagiline (azilect) or selegiline.
For the first year, one-third of the cohort will receive placebo and one-third a low dose of antibody, 1,500 mg. The remainder will take a high dose, which will vary by body weight—3,500 mg for people under 65 kg; 4,500 for those 65 kg or heavier. The high dose is roughly equivalent to the highest dose tested in Phase 1, 60 mg/kg.
Is anyone on HU in this trial? If so, would be very helpful to hear about your experience!
For more information on the Prothena Phase 2 clinical study of PRX002/RG7935 in patients with Parkinson's disease, visit clinicaltrials.gov and search NCT #03100149.